Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
32.3M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
29.7M
-
Shares change
-
+3.61M
-
Total reported value, excl. options
-
$769M
-
Value change
-
+$87.6M
-
Number of buys
-
46
-
Number of sells
-
-45
-
Price
-
$25.88
Significant Holders of Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) as of Q2 2024
103 filings reported holding DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share as of Q2 2024.
Dianthus Therapeutics, Inc. /DE/ - Common Stock, $0.001 par value per share (DNTH) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.7M shares
of 32.3M outstanding shares and own 92.08% of the company stock.
Largest 10 shareholders include FMR LLC (4.4M shares), Bain Capital Life Sciences Investors, LLC (3.01M shares), Avidity Partners Management LP (2.92M shares), Fairmount Funds Management LLC (2.76M shares), RA CAPITAL MANAGEMENT, L.P. (2.33M shares), VR Adviser, LLC (2.09M shares), Octagon Capital Advisors LP (1.75M shares), BlackRock Inc. (1.6M shares), VANGUARD GROUP INC (1.25M shares), and 5AM Venture Management, LLC (1.23M shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.